<jats:title>Abstract</jats:title><jats:p><jats:italic>MET</jats:italic> mutations leading to exon 14 skipping (<jats:italic>MET</jats:italic>Δex14) are strong molecular drivers for non–small‐cell lung cancer (NSCLC). Capmatinib is a highly potent, selective oral MET inhibitor that showed clinically meaningful efficacy and a manageable safety profile in a global phase II study (GEOMETRY mono‐1, NCT02414139) in patients with advanced <jats:italic>MET</jats:italic>Δex14‐mutated/<jats:italic>MET</jats:italic>‐amplified NSCLC. We report results of preplanned analyses of 45 Japanese patients according to <jats:italic>MET</jats:italic> status (<jats:italic>MET</jats:italic>Δex14‐mutated or <jats:italic>MET</jats:italic>‐amplified) and line of therapy (first‐ [1L] or second‐/third‐line [2/3L]). The starting dose was 400 mg twice daily. The primary endpoint was the objective response rate (ORR) assessed by a blinded independent review committee. A key secondary endpoint was duration of response (DOR). Among <jats:italic>MET</jats:italic>Δex14‐mutated patients, in the 1L group, one patient achieved partial response (DOR of 4.24 months) and the other had stable disease. In the 2/3L group, the ORR was 36.4% (95% confidence interval [CI] 10.9%‐69.2%), median DOR was not evaluable, and progression‐free survival was 4.70 months. One patient (2/3L group) showed partial resolution of brain lesions per independent neuroradiologist review. In <jats:italic>MET</jats:italic>‐amplified patients with a <jats:italic>MET</jats:italic> gene copy number of ≥10, the ORR was 100% (2/2 patients) in the 1L group and 45.5% (5/11 patients) in the 2/3L group, with DOR of 8.2 and 8.3 months, respectively. Common treatment‐related adverse events among the 45 Japanese patients were blood creatinine increased (53.3%), nausea (35.6%), and oedema peripheral (31.1%); most were grade 1/2 severity. In conclusion, capmatinib was effective and well tolerated by Japanese patients with <jats:italic>MET</jats:italic>Δex14/<jats:italic>MET</jats:italic>‐amplified NSCLC, consistent with the overall population.</jats:p>